Han JY - Search Results

1

A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.

Han JY, Lim KY, Yu SY, Yun T, Kim HT, Lee JS. Han JY, et al. Cancer. 2011 May 15;117(10):2178-85. doi: 10.1002/cncr.25790. Epub 2010 Nov 30. Cancer. 2011. PMID: 21523731 Free article. Clinical Trial.

2

Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis.

Han JY, Kim HS, Lee SH, Park WS, Lee JY, Yoo NJ. Han JY, et al. Lung Cancer. 2003 Jul;41(1):65-70. doi: 10.1016/s0169-5002(03)00146-6. Lung Cancer. 2003. PMID: 12826314

3

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.

Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, Lee HG, Lee SY, Shin EH, Lee JS. Han JY, et al. Cancer. 2003 Nov 1;98(9):1918-24. doi: 10.1002/cncr.11738. Cancer. 2003. PMID: 14584075 Free article. Clinical Trial.

4

A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.

Han JY, Lee DH, Kim HY, Kim EA, Lee JJ, Ju SY, Shin EH, Lee JS. Han JY, et al. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5909-14. Clin Cancer Res. 2003. PMID: 14676114 Clinical Trial.

5

Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer.

Han JY, Hong EK, Choi BG, Park JN, Kim KW, Kang JH, Jin JY, Park SY, Hong YS, Lee KS. Han JY, et al. Med Oncol. 2003;20(4):355-62. doi: 10.1385/MO:20:4:355. Med Oncol. 2003. PMID: 14716031 Clinical Trial.

6

Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.

Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK, Lee JS. Lee DH, et al. Among authors: han jy. Clin Cancer Res. 2005 Apr 15;11(8):3032-7. doi: 10.1158/1078-0432.CCR-04-2149. Clin Cancer Res. 2005. PMID: 15837758 Clinical Trial.

7

Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.

Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, Lee JS. Han JY, et al. J Clin Oncol. 2005 May 20;23(15):3488-94. doi: 10.1200/JCO.2005.01.082. J Clin Oncol. 2005. PMID: 15908658 Clinical Trial.

8

Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.

Kim TH, Cho KH, Pyo HR, Lee JS, Han JY, Zo JI, Lee JM, Hong EK, Choi IJ, Park SY, Shin KH, Kim DY, Kim JY. Kim TH, et al. Among authors: han jy. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):995-1002. doi: 10.1016/j.ijrobp.2004.12.025. Int J Radiat Oncol Biol Phys. 2005. PMID: 15990000

9

Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.

Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ, Lee JS. Lee DH, et al. Among authors: han jy. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1037-44. doi: 10.1016/j.ijrobp.2005.04.034. Epub 2005 Jul 18. Int J Radiat Oncol Biol Phys. 2005. PMID: 16024178 Clinical Trial.

10

A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.

Han JY, Lee DH, Lee SY, Park CG, Kim HY, Kim EA, Yoon SM, Lee HG, Lee JS. Han JY, et al. Med Oncol. 2005;22(3):281-90. doi: 10.1385/MO:22:3:281. Med Oncol. 2005. PMID: 16110139 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,103 results

Search Page

Filters